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Dimethyl fumarate blocks pro-
inflammatory cytokine production 
via inhibition of TLR induced M1 
and K63 ubiquitin chain formation
Victoria A. McGuire1, Tamara Ruiz-Zorrilla Diez1,2, Christoph H. Emmerich3, Sam Strickson3, 
Maria Stella Ritorto3, Ruhcha V. Sutavani1, Anne Weiβ 1, Kirsty F. Houslay1, Axel Knebel3, 
Paul J. Meakin4, Iain R. Phair1, Michael L. J. Ashford4, Matthias Trost3 & J. Simon C. Arthur1
Dimethyl fumarate (DMF) possesses anti-inflammatory properties and is approved for the treatment of 
psoriasis and multiple sclerosis. While clinically effective, its molecular target has remained elusive -  
although it is known to activate anti-oxidant pathways. We find that DMF inhibits pro-inflammatory 
cytokine production in response to TLR agonists independently of the Nrf2-Keap1 anti-oxidant 
pathway. Instead we show that DMF can inhibit the E2 conjugating enzymes involved in K63 and M1 
polyubiquitin chain formation both in vitro and in cells. The formation of K63 and M1 chains is required 
to link TLR activation to downstream signaling, and consistent with the block in K63 and/or M1 chain 
formation, DMF inhibits NFκB and ERK1/2 activation, resulting in a loss of pro-inflammatory cytokine 
production. Together these results reveal a new molecular target for DMF and show that a clinically 
approved drug inhibits M1 and K63 chain formation in TLR induced signaling complexes. Selective 
targeting of E2s may therefore be a viable strategy for autoimmunity.
Autoimmune disorders represent a diverse range of conditions that remain challenging to treat. The advent of bio-
logical drugs, such as anti-TNF agents, provided a significant advance in the treatment of these conditions1, how-
ever they have the disadvantages of not being orally available and that a proportion of patients do not respond. 
The development of new orally available small molecule drugs for autoimmunity is therefore desirable. Several 
breakthroughs in this area have recently been made, such as the development of Jak inhibitors and S1P receptor 
modulating agents, which illustrate the potential of this approach2–4.
Dimethyl fumarate (DMF) is a methyl ester known to have immuno-modulatory properties. In combination 
with other fumaric acid esters, DMF has been in use for many years as a treatment for moderate and severe pso-
riasis5. The first report of its use was in 19596, although it did not gain widespread acceptance until some time 
later following the publication of the first clinical trials demonstrating its efficacy in 19907. Subsequently, DMF in 
combination with three salts of ethylhydrogenfumarate was licensed for use in psoriasis in Germany in 19948,9. 
More recently, a slow release formulation of DMF has been approved for the treatment of multiple sclerosis10.
The molecular target of DMF that accounts for its ability to modulate the immune system has been elusive. 
Amongst the possible explanations for its action, DMF has been shown to reduce T cell numbers, inhibit NFκ 
B mediated transcription and activate the Nrf2 pathway (reviewed in11,12). In addition, DMF has been found to 
modulate cytokine production in a number of immune cell types: cytokine production is regulated by several 
intracellular signaling systems including NFκ B and the ERK1/2 and p38 MAPK pathways, and DMF has been 
suggested to modulate these pathways. For example, DMF has been shown to prevent the induction of NFκ 
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B dependent transcription in LPS stimulated dendritic cells as well as TNF stimulated Human Umbilical Vein 
Endothelial Cells (HUVEC) or airway smooth muscle cells (ASMC)13–15.
The reported effects of DMF on MAPK signaling are less clear. While some studies have shown that DMF 
could decrease ERK1/2 activation in cells, others have found it to have no effect14,16,17. For p38, DMF has been 
reported to either have no effect on activation or to result in an increase in p38 phosphorylation14,18. MAPKs 
can, in part, mediate their cellular effects via the activation of downstream kinases. For example, p38α activates 
the downstream kinases MK2 and MK3 to promote the production of TNF19. In addition, p38α can also activate 
the kinases MSK1 and MSK220. These two kinases, which can also be activated by ERK1/220, have been found to 
have anti-inflammatory functions in macrophages and are required for the maximal induction of IL-10 by mac-
rophages and dendritic cells21,22. The ERK1/2 pathway can also activate RSK23, however the role that this kinase 
plays in the regulation of cytokine production is less well established. DMF has been shown to affect the activation 
of both MSKs and RSKs14,16,17. For instance, in keratinocytes DMF selectively blocked MSK1 phosphorylation 
but not ERK1/2 or p38α activation in response to IL-1 stimulation16. Similarly DMF also blocked MSK1 and 
RSK activation in MIF (Macrophage Inhibitory Factor) stimulated keratinocytes and prevented the induction of 
Cox217, a known MSK target gene24. DMF has also been reported to inhibit MSK1 phosphorylation in LPS stim-
ulated dendritic cells, however in contrast to the data in keratinocytes, in dendritic cells DMF was able to reduce 
LPS induced ERK1/2, although not p38 or JNK, phosphorylation14.
In this study we examine the mechanism by which DMF blocks cytokine induction in primary macrophages 
and demonstrate that it affects signaling by inhibiting the formation of M1/K63 hybrid polyubiquitin chains.
Results
DMF inhibits the transcription of cytokines independently of Nrf2. To test the ability of DMF to 
block cytokine production in response to TLR agonists, BMDMs were incubated with various concentrations of 
DMF for 4 h (Fig. 1A). The cells were then stimulated with the TLR4 agonist LPS for a further 8 h and cytokine 
release determined. LPS promoted the secretion of TNF, IL-6, IL-10, IL-13 and GM-CSF; this was blocked by 50 μ M 
DMF (Fig. 1A). To ensure this was not due to a loss of cell viability, cells were incubated with 50 μ M DMF and 
viability determined by FACS. DMF did cause some cell death that increased over time, however the majority 
of cells were still alive following 12 h of DMF treatment (Fig. 1B). Cells were then treated with or without DMF 
in the presence of brefeldin A and monensin to block cytokine secretion. TNF levels were then measured at a 
single cell level by flow cytrometry following gating on the live cell population. This showed that DMF blocked 
LPS stimulated TNF production in the live cells (Fig. 1C). In line with the loss of cytokine secretion (Fig. 1A), 
DMF also repressed the induction of various cytokine mRNAs, including TNF, IL-6, IL-10, GM-CSF, IL-12p40, 
IL-23p19 and IFNβ , in response to 1 h of LPS stimulation (Fig. 2). DMF also suppressed the induction of Iκ Bα 
mRNA, an established NFκ B target gene.
DMF has previously been suggested to act via targeting cysteine residues in Keap1 and activating the Nrf2 
anti-oxidant pathway25–27. To test the potential involvement of this pathway in the regulation of cytokine tran-
scription, Nrf2− /− BMDMs were stimulated with LPS in the presence or absence of DMF and cytokine mRNA 
levels measured at 1 h. Nrf2 regulates the transcription of several genes including HO-128,29. While LPS alone 
did not induce the mRNA for HO-1, this mRNA was induced in DMF treated wild type but not Nrf2 knockout 
BMDMs, indicating that DMF was able to activate Nrf2 in macrophages (Fig. 3). Nrf2 knockout did not affect 
the induction of TNF, IL-6, IL-12p40, IL-23p19 or Iκ Bα mRNAs in response to LPS relative to wild type cells. 
There was a small but significant increase (p < 0.05, Students unpaired two tailed t-test) in LPS stimulated IL-10 
and GM-CSF mRNA induction in Nrf2 knockout cells compared to wild type BMDMs (Fig. 3). This increase in 
IL-10 mRNA induction is consistent with a recent report showing increased IL-10 production in Nrf2 knockout 
dendritic cells30. DMF was able to inhibit cytokine and Iκ Bα mRNA induction in response to LPS in both wild 
type and Nrf2− /− cells (Fig. 3). These results suggest that the effects of DMF on LPS induced cytokine induction 
are largely independent of any effects on the Nrf2 pathway.
DMF has been proposed to inhibit the action of MSK1 in dendritic cells14. However, the reduced cytokine 
production caused by DMF in Fig. 1 is inconsistent with the decreased IL-10 production but increased 
pro-inflammatory cytokine production previously reported in MSK1/2 double knockout macrophages22, sug-
gesting that DMF must have MSK independent effects. To confirm this, wild type and MSK1/2 knockout BMDCs 
were tested. As expected MSK1/2 knockout BMDCs exhibited a lower induction of the MSK1/2 target gene IL-10 
relative to wild type cells (Fig. 4). Induction of IL-12p35 mRNA was increased in the MSK1/2 knockout BMDCs 
while IL-6, IL-12p40 and Iκ Bα mRNA induction was not greatly changed. As in macrophages, DMF blocked the 
LPS induced expression of both Iκ Bα and the cytokine mRNAs tested. This inhibition was comparable in wild 
type and MSK1/2 knockout cells (Fig. 4).
DMF inhibits NFκB and ERK1/2 activation in response to TLR agonists. TLR dependent tran-
scription and secretion of cytokines is regulated by the NFκ B as well as the ERK1/2 and p38 MAPK signaling 
pathways31. The ability of DMF to block the induction of multiple LPS induced genes (Figs 1 and 2) suggested 
that it might have a suppressive effect on both MAPK and NFκ B activation in response to the TLR4 agonist LPS. 
TLR4 signals via both MyD88 and Trif dependent pathways, which are thought to converge on the activation of 
Tak131–34. Tak1 in turn activates a complex of IKKβ , IKKα and NEMO. IKKβ then activates the classical NFκ B 
pathway via the phosphorylation of Iκ Bα . In addition IKKβ also phosphorylates p105, and this is required for 
the activation of Tpl2, which is then able to activate the ERK1/2 pathway. Tak1 also directly activates the MKKs 
required for the activation of the p38 and JNK pathways (Fig. 5A)31–34.
DMF was able to inhibit the activation of the classical NFκ B pathway, as 50 μ M of DMF was sufficient to block 
the degradation of Iκ Bα in response to 30 min stimulation with LPS (Fig. 5B). In addition, 50 μ M DMF blocked 
the phosphorylation of IKKβ on Ser177 and 181 (Fig. 5B), sites that correlate with its activation35. In agreement 
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with the loss of IKKβ activity, DMF also blocked the phosphorylation of the IKKβ substrate p105 and inhibited 
the activation of ERK1/2, as judged by phosphorylation on its TXY activation motif. DMF treatment also resulted 
in a partial inhibition of JNK activation, that was maximal at 75 μ M DMF. In contrast, DMF did not inhibit the 
Figure 1. Inhibition of LPS stimulated cytokine induction by DMF. (A) BMDMs were incubated with 0, 
25, 50, 75 or 100 μ M DMF for 4 h. Cells were then stimulated with 100 ng/ml LPS for 8 h and the levels of TNF, 
IL-6, IL-10, IL-13 and GM-CSF determined. (B) BMDMs were incubated with 50 μ M DMF for the indicated 
times and cell viability was determined by staining with Zombie-Aqua. Results show average and standard 
deviation of 4 independent treatments. (C) BMDMs were incubated in 50 μ M DMF where indicated. Cells were 
then stimulated with 100 ng/ml LPS for 5 h. Cells were then stained for intracellular TNF levels and viability 
(Zombie-Aqua) as described in the methods. Representative stimulations are shown in the FACS plots while 
the graphs show average and standard deviation from 3 independent stimulations. In (A,C) a p value (Students 
t-test) of less than 0.001 relative to the LPS alone condition is indicated by * * * .
www.nature.com/scientificreports/
4Scientific RepoRts | 6:31159 | DOI: 10.1038/srep31159
activation of p38 at any of the concentrations tested. In the MyD88 pathway, IRAKs are involved in propagating 
the signal from MyD88 to Traf6 and then Tak1. During this process IRAK1 becomes modified with K63 poly-
ubiquitin chains, resulting in the disappearance of the IRAK1 band at its predicted molecular weight on immu-
noblots that can be reversed by treatment of the lysates with deubiquitinating enzymes36,37. Interestingly, the loss 
of the IRAK1 band was partially reversed by 25 μ M DMF and completely reversed by 50 μ M DMF suggesting that 
DMF may interfere with IRAK1 ubiquitination (Fig. 5B).
To examine this process in more detail, cells were incubated in 50 μ M DMF and then a time course of LPS 
stimulation carried out (Fig. 5C). As in the previous experiment, DMF inhibited the loss of IRAK1 and Iκ Bα , 
blocked the phosphorylation of IKKβ and p105 and greatly reduced the phosphorylation of ERK1/2. The effect 
on JNK phosphorylation was more complex. DMF reduced the phosphorylation of JNK at 30 min. In the absence 
of DMF, JNK phosphorylation was transient and not observed at 60 or 90 min. In contrast, JNK phosphorylation 
was still observed at 60 and 90 min of LPS stimulation in the presence of DMF.
LPS has the ability to signal via both the MyD88 and Trif adaptors. To determine if the effects of DMF on 
signaling were common to pathways downstream of both adaptors, cells were stimulated with either Pam3CSK4 
or poly(I:C). Pam3CSK4 stimulates TLR1/2 and acts via MyD88 and not Trif. The effects of DMF on Pam3CSK4 
induced signaling mirrored the results seen with LPS (Fig. 5C). Poly(I:C) activates TLR3 and this utilizes Trif and 
not MyD88 for downstream signaling. Consistent with this poly(I:C) did not strongly promote the ubiquitination 
of IRAK1. Poly(I:C) was able to induce both IKKβ and p105 phosphorylation and this was blocked by DMF. In 
addition DMF blocked poly(I:C) induced ERK1/2 activation, however, as for LPS and Pam3CSK4 there was little 
effect on p38 activation (Fig. 5C). Poly(I:C) was only a weak activator of JNK, and this activation was slightly 
increased in the presence of DMF.
Unexpectedly in these experiments, incubation in DMF alone induced the phosphorylation of p38 and, to a 
lesser extent, JNK in the absence of any other stimuli (Fig. 5C, lane 5). To examine this further a time course of 
DMF treatment alone was carried out. DMF treatment in the absence of any additional TLR stimulation did not 
affect IRAK1 ubiquitination or p105 phosphorylation (Fig. 6A). DMF treatment did however induce phospho-
rylation of p38, and to a lesser extent JNK, over time. Tyrosine phosphatase inhibitors have previously been found 
to activate MAPK signaling in cells38. Tyrosine phosphatases possess an active site cysteine and may therefore be 
a target for electrophilic drugs such as DMF39. Treatment with the tyrosine phosphatase inhibitor pervanadate 
induced the phosphorylation of p38 and JNK although, in contrast to DMF, pervanadate also strongly induced 
ERK1/2 phosphorylation (Fig. 6A). As would be expected pervanadate strongly induced global tyrosine phospho-
rylation levels. In contrast, DMF had little effect on global tyrosine phosphorylation levels indicating that it does 
not act as a general tyrosine phosphatase inhibitor in cells (Fig. 6B). MAPKs can be dephosphorylated by DUSPs 
Figure 2. DMF inhibits LPS induced gene transcription. BMDMs were incubated with 50 μ M DMF for 
4 h and then stimulated with LPS for 1 h as indicated. Total RNA was then isolated and the induction of TNF, 
IL-6, IL-10, GM-CSF, IL-12p40, IL-23p19, Iκ Bα and IFNβ determined by qPCR as described in the methods. 
Error bars represent the standard deviation of 4 BMDM cultures. For a comparison of LPS stimulation with or 
without DMF treatment a p value (Students t-test) of < 0.01 is indicated by * * and p < 0.001 by * * * .
www.nature.com/scientificreports/
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(Dual Specificity Phosphatases) and inhibition of these enzymes by DMF may account for the p38 and JNK 
activation. Inhibition of the DUSP would be expected to be specific for the MAPK and not affect the upstream 
MKK. DMF was found to increase the phosphorylation of MKK3 and 6 suggesting that its effects on p38 and JNK 
phosphorylation were independent of DUSP inhibition (Fig. 6A).
Figure 3. Effect of DMF on LPS stimulated mRNA induction in Nrf2 knockout BMDMs. BMDMs were 
isolated from wild type and Nrf2 knockout mice. Cells were incubated with 50 μ M DMF for 4 h and then 
stimulated with LPS for 1 h as indicated. Total RNA was then isolated and the induction of TNF, IL-6, IL-10,  
GM-CSF. IL-12p40, IL-23p19, Iκ Bα and HO-1 determined by qPCR. Error bars represent the standard 
deviation of measurements from independent cultures from 4 mice per genotype. For a comparison of LPS 
stimulation in the presence and absence of DMF a p value (Students t-test) of < 0.05 in indicated by * , p < 0.01 
by * * and p < 0.001 by * * * . For a comparison between wild type and Nrf2 knockout cells a p < 0.05 is indicated 
by # and p < 0.01 by ##.
www.nature.com/scientificreports/
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Figure 4. Effect of DMF on LPS stimulated mRNA induction in MSK1/2 knockout BMDCs. BMDCs were 
isolated from wild type and MSK1/2 double knockout mice. Cells were incubated with 50 μ M DMF for 4 h and 
then stimulated with LPS for 1 h or 16 h as indicated. Total RNA was then isolated and the induction of IL-10, 
IL-6, GM-CSF, IL-12p35, IL-12p40 and Iκ Bα was determined by qPCR. Error bars represent the standard 
deviation of measurements from independent cultures from 4 (0 and 1 h) or 3 (16 h) mice per genotype. A 
p value (Students t-test) between the presence and absence of DMF of less that 0.01 is indicated by * * and a 
p < 0.001 by * * * . For a comparison of wild type and MSK1/2 knockout cells in the absence of DMF, p < 0.05 
and p < 0.01 are indicated by # and ## respectively.
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DMF has the ability to covalently modify cysteine residues in its targets, as is proposed for Keap1. We assessed 
whether DMF inhibition remained following washout of DMF from the cells. BMDMs were treated for 4 h with 
50 μ M DMF and then either directly stimulated with LPS or washed extensively and incubated in media without 
DMF for various times. This showed that signaling was still inhibited by DMF 4 h after DMF being washed off 
the cells, but that inhibition was lost by 16 h (Fig. 6C). This slow loss of inhibition would be consistent with DMF 
covalently modifying its target in cells.
Figure 5. DMF inhibits multiple signals downstream of TLR4. (A) TLR4 activates both NFκ B and MAPK 
pathways via Tak1 and IKK in order to drive cytokine production. (B) BMDMs were treated with the indicated 
concentrations of DMF for 4 h. Cells were then stimulated with 100 ng/ml LPS for 30 min. Following cell lysis 
the levels of the indicated total and phospho proteins were determined by immunoblotting. (C) BMDMs were 
cultured in the presence or absence of 50 μ M DMF for 4 h. Cells were then further stimulated for the indicated 
times with either 100 ng/ml LPS, 1 μ g/ml Pam3CSK4 or 10 μ g/ml poly(I:C). The levels of the indicated total and 
phospho proteins were determined by immunoblotting.
www.nature.com/scientificreports/
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In vivo DMF can be converted to MMF. We therefore checked if MMF was able to mimic the effects of DMF 
on cell signaling. Unlike DMF, MMF did not inhibit LPS induced ERK1/2 or p105 phosphorylation, or the ubiq-
uitination of IRAK1 (Supplementary Figure 1).
DMF inhibits E2 conjugating enzymes in vitro. Together these results suggest that DMF may act at 
an upstream point in the TLR signaling cascade. The activation of Tak1 and the recruitment of the IKK com-
plex involves the formation of K63/M1 hybrid polyubiquitin chains which can be added to several proteins in 
the MyD88 signaling cascade including MyD88 and IRAKs34,40. The formation of polyubiquitin chains requires 
a cascade of three enzymes; an E1 activating enzyme, an E2 conjugating enzyme and an E3 ligase to mediate 
the transfer of the ubiquitin to the substrate. E2 enzymes use a cysteine in their active site to covalently couple 
to ubiquitin. DMF is an electrophilic compound and therefore has the potential to react with the SH group in 
cysteines (Fig. 7A). We therefore investigated if DMF could inhibit Ubc13 or UbcH7, the major E2 enzymes pro-
posed to be involved in the formation of K63 and M1 chains41–45. In vitro, addition of the E1 UBE1, ubiquitin and 
Mg-ATP to an E2 is able to promote the loading of ubiquitin onto the E2, which can be resolved as a mobility shift 
on SDS polyacrylamide gels45. Addition of DMF to this reaction inhibited the loading of ubiquitin onto Ubc13 
with an IC50 of between 10 and 20 μ M (Fig. 7B). In parallel assays, UbcH7 was more strongly inhibited by DMF 
with an IC50 of less than 10 μ M and complete inhibition by 50 μ M (Fig. 7B). If DMF were to inhibit Ubc13 or 
UbcH7 via covalent modification of a cysteine, the molecular mass of the E2 should be increased following DMF 
treatment. MALDI-TOF mass spectrometry was therefore used to determine the molecular mass of recombinant 
Ubc13 and UbcH7 before and after treatment with DMF. The recombinant Ubc13 has a theoretical mono-isotopic 
Figure 6. DMF can activate p38 MAPK and can covalently modify its targets in the cell. BMDMs were 
incubated in 50 μ M DMF for the indicated times. Alternatively BMDMs were stimulated with 100 ng/ml LPS 
for 30 min (L) or 60 μ M sodium pervanadate for 10 min (P). (A) The levels of the indicated total and phospho 
proteins were determined by immunoblotting. (B) Lysates from A were immunoblotted for p-Tyr. Molecular 
weights (kDa) are indicated on the left and two exposures are shown. (C) Where indicated BMDMs were treated 
with 50 μ M DMF for 4 h. Cells were then washed 3 times to remove the DMF and incubated for the indicated 
washout times. Finally cells were stimulated with 100 ng/ml LPS for 30 min. The levels of the indicated total and 
phospho proteins were determined by immunoblotting.
www.nature.com/scientificreports/
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mass of 17295 Da, which corresponded well with the observed mass of 17301 Da. For Ubc13, an increase in the 
molecular mass of 144 Da was seen following incubation in DMF, which would be consistent with the labeling 
Figure 7. DMF can inhibit E2 conjugating enzymes in vitro. (A) Reaction mechanism of DMF and cysteine. 
(B) Ubc13 or UbcH7 was incubated in the presence or absence of DMF for 30 minutes. E2 loading reactions 
for Ubc13 and UbcH7 in the presence of ubiquitin, Ube1 and Mg-ATP were carried out in the presence of 
increasing concentrations of DMF as described in the methods. Ubiquitin loading was resolved on 4-12% 
polyacrylamide gels. Example gels are shown on the left and the quantification of 3 separate reactions shown 
on the right. Error bars represent standard deviation. For DMF treated conditions, a p value of less than 0.001 
(Students t-test) is indicated by * * * . (C) Ubc13 or UbcH7 was incubated in the presence or absence of 50 μ M  
DMF for 4 h. The molecular mass was then determined by MALDI-TOF mass spectrometry. Spectra show 
intensity vs. m/z and inserts show an expansion of the 2+ peak. (D) The indicated E2 conjugating enzymes were 
incubated with either 25 or 100 μ M DMF for 30 minutes and E2 loading assays carried out as described in the 
methods. The % E2 loading relative to the 0 μ M condition for each E2 tested is shown.
www.nature.com/scientificreports/
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of a cysteine residue in the protein with DMF via a Michael addition reaction (Fig. 7A). For unmodified UbcH7 
a mass of 18157 Da was observed relative to a theoretical mono-isotopic mass of 18149 Da. Following DMF 
treatment of UbcH7 3 peaks were obtained. The major peaks indicated an addition of 144 and 289 Da, which 
would correspond to addition of 1 or 2 DMF molecules respectively. A minor peak was also obtained with a mass 
increase of 432 Da, which would suggest addition of 3 molecules of DMF (Fig. 7C). Of note, Ubc13 only contains 
the active site cysteine whereas UbcH7 also contains 2 further cysteines in addition to its reactive site residue. 
To further test the ability of 50 or 100 μ M DMF to block E2 activity, it was tested against a panel of 24 different 
E2 enzymes (Fig. 7D). This showed that while DMF could inhibit all the E2’s tested to some extent, it did exhibit 
some selectivity with UbcH7, Ube2W, Ube2T, Ube2S and Ube2R1 being most strongly inhibited.
DMF blocks the formation of M1 and M1/K63 polyubuititin chains downstream of TLR signaling. 
Previous studies have indicated that TLR agonists can stimulate the formation of K63/M1 hybrid polyubiquitin 
chains40,46. As, in vitro, DMF inhibited Ubc13 and UbcH7, the E2 conjugating enzymes proposed to be involved 
in the formation K63 and M1 chains respectively, its ability to block formation of M1 and K63 chains in cells 
was determined. M1-Ub chains were pulled down from RAW264.7 macrophage cell lysates using Halo-tagged 
NEMO beads, which shows > 50 fold selectivity for M1 relative to K63 chains40. This approach would be expected 
to pull down M1-Ub chains, complexes containing both M1 and K63 chains as well as M1/K63 hybrid chains 
that are proposed to be formed downstream of TLR signaling40,46. As seen in primary macrophages following 
TLR stimulation, DMF inhibited the ubiquitination of IRAK1 and the phosphorylation of ERK1/2, p105 and 
IKK in RAW264.7 cells (Fig. 8A). Halo-NEMO pulldowns were blotted for M1 or K63 polyubiquitin chains 
on IRAK1 and IRAK2. LPS increased the amount of M1 and M1/K63 hybrid chains in the pulldowns, and this 
increase was inhibited by pretreatment of the cells with DMF (Fig. 8B). Polyubiquitinated IRAK1 and IRAK2 
could also be seen in the pulldowns from LPS stimulated but not untreated cells, and this was blocked by pretreat-
ment with DMF (Fig. 8B). DMF did not however block all ubiquitination within the cell. Halo-TUBE (Tandem 
Ubiquitin Binding Entities) beads were used to pull down all ubiquitin chains within the cells. Blotting of these 
pulldowns showed that LPS did not increase the total amount of K11, K48 or K63 linked polyubiquitin chains in 
these pull downs and that these levels were also not reduced by DMF (Supplementary Figure 2). Similarly using 
Halo-TAB2-NFZ beads to pull down K63 chains showed that neither LPS or DMF affected the amount of K63 
chains in these pull downs (Supplementary Figure 2). This probably reflects a high background level of K63 and 
K48 chains within the cell so that the changes induced by TLR signaling are too small to be seen. In line with 
this, blotting the Halo-TUBE or Halo-TAB2-NFZ pull downs for IRAK2 showed that LPS did induce the ubiq-
uitination of this protein and that this was blocked by DMF (supplementary Figure 2). In line with the results in 
RAW264.7 cells, DMF also greatly reduced the amount of M1 chains that could be pulled down from BMDM 
lysates using either Halo-NEMO or Halo-TUBE beads (Fig. 9). Similarly the amount of ubiquitinated IRAK2 
that came down in the Halo-NEMO pulldowns was also reduced by DMF. In contrast, DMF did not reduce the 
amount of K48 linked chains in Halo-TUBE pulldowns from BMDMs (Fig. 9).
M1 chains are formed by the LUBAC complex which contains HOIP, HOIL and Sharpin. In this complex 
HOIP acts as the E3 and directly conjugates to ubiquitin via a cysteine during ubiquitin transfer47. As it is possible 
that DMF might inhibit HOIP via reacting with this cysteine in cells, HOIP was immunoprecipitated from cells 
and its activity examined in an in vitro ubiquitination reaction. Due to the covalent modification of the cysteine 
by DMF, inhibition in the cell should be retained during the immunoprecipitation and in vitro assay. Consistent 
with previous reports40, HOIP was constitutively active in this assay, and this activity was not affected by pretreat-
ment of the cells with DMF (Supplementary Figure 3).
DMF inhibits K63/M1 chain formation in response to IL-1 and TNF. The formation of K63 and M1 
chains is not restricted to TLR signaling and also occurs downstream of other stimuli including IL-1 and TNF34,40. 
To examine chain formation downstream of IL-1, HEK293 cells stably expressing the IL-1 receptor were stimu-
lated with IL-1 in the presence or absence of DMF. In these cells IL-1 stimulated the phosphorylation of p105 and 
IKK as well as the degradation of Iκ Bα which was blocked by DMF, as was the activation of ERK1/2 (Fig. 10A). 
In Halo-NEMO pulldowns, IL-1 stimulation increased the amount of both M1 and K63 chains observed, and 
this was blocked by pretreatment of the cells with DMF (Fig. 10B). Treatment of HeLa cells with TNF induced 
ERK1/2, IKK and p105 phosphorylation as well as the degradation of Iκ Bα . ERK1/2 phosphorylation and Iκ Bα 
degradation were inhibited by DMF, however in these cells DMF did not block p105 or IKK phosphorylation in 
response to TNF (Fig. 10C). NEMO pulldowns showed that TNF stimulated the formation of M1 polyubiquitin 
chains, and this was reduced by DMF. TNF only resulted in a minor increase in the signal for K63 chains, but 
again this was reduced by DMF (Fig. 10D).
Discussion
While the ability of DMF to modulate immune function is well established, its mechanism of action has been 
more elusive, and several potential in vivo targets have been suggested. While DMF can activate the Nrf2 
anti-oxidant pathway, our results, along with those recently published by Gillard et al.48, indicate that this is not 
required for the ability of DMF to block cytokine induction. In our hands DMF has a suppressive effect on several 
pathways downstream of TLR signaling, including NFκ B and ERK1/2 signaling. We demostrate here that DMF 
can inhibit cytokine production in macrophages and that this correlates to the inhibition of NFκ B and MAPK 
signaling pathways. This would suggest that DMF acts at an upstream point in TLR signaling, and in line with this 
we show that DMF can block the formation of signaling complexes containing M1 and K63 polyubiquitin chains 
downstream of TLR and IL-1 signaling. Furthermore, in vitro DMF can inhibit UbcH7 and Ubc13, the major E2 
enzymes thought to be required for K63 and M1 chain formation in response to IL-1 or TLR agonists. DMF did 
not result in a global loss of polyubiquitin chains. Notably the levels of K63 and K48 chains in pull downs with 
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Halo-TUBE beads was unaffected by DMF. One explanation is that the majority of these chains were preformed in 
the cell prior to the addition of DMF. If the turnover of the chains was slow, no effect of DMF would be expected 
on the levels of these chains. In line with this, LPS did not increase the levels of either K48 or K63 chains in the 
Halo-TUBE pulldowns indicating the presence of a significant number of K48 and K63 cells in resting cells. These 
observations does not mean TLR signaling cannot promote the K48 or K63 linked ubiquitination of specific pro-
teins only that any such modifications do not measurably alter the total amount of K48 and K63 chains in the cell. 
TLR signaling has been shown to promote K63 and M1 polyubiquitin chain formation on a number of signaling 
proteins including IRAK1. Previous reports have indicated that many of these chains actually from as hybrids of 
K63 and M1 chains40,46, and in line with this we see increased amounts of K63 and M1 chains in pull downs with 
Halo-NEMO beads, which selectively pulls down complexes containing M1 chains. The TLR induced formation 
of these K63 and M1 chains was blocked by pretreatment with DMF (Figs 8–10).
DMF is converted to MMF in vivo. The effects we observed on signaling were specific for DMF, as we did not 
observe any effect of MMF on LPS induced signaling. This is in agreement with a previous study showing that 
DMF, but not MMF, repressed TLR induced cytokine induction in primary human PBMCs48. In macrophages 
we show that DMF blocked the activation of the IKK complex and thus prevented both p105 phosphorylation 
and Iκ Bα degradation. Previous reports have also indicated that DMF may inhibit NFκ B transcriptional activity. 
For example, DMF reduced NFκ B activity in LPS stimulated dendritic cells and TNF stimulated HUVEC or 
Figure 8. Effect of DMF on LPS stimulated polyubiquitin chain formation in RAW264.7 macrophages. 
RAW264.7 cells were incubated in the presence or absence of 50 μM DMF for 4 h. Cells were then either 
left unstimulated or treated with 100 ng/ml LPS for a further 30 min. Cells were lysed and lysates were blotted 
for the phospho and total proteins indicated (A). Alternatively, Halo-NEMO beads were used to pulldown M1 
polyubiquitin chains. Pull downs were then immunoblotted with antibodies specific for M1 chains, K63 chains, 
IRAK1 or IRAK2. Total ubiquitin was pulled down using Halo-TUBE beads and blotted for the presence of K48 
chains (B).
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ASMC13–15. A common feature of these earlier studies was that DMF inhibited NFκ B DNA binding or relocali-
zation to the nucleus, but did not have a major effect on the degradation of Iκ Bα . The reason for the difference 
between these studies and our findings is not clear. One potential explanation is the different cell types and 
stimuli used in the various studies may influence the results seen for Iκ Bα degradation. In line with this, the 
ability of DMF to inhibit Iκ Bα degradation in TNF stimulated HeLa cells was much less than in TLR stimulated 
macrophages. Another issue could relate to how DMF was used. The concentrations of DMF were similar in 
the different studies, however the pre-incubation times in these previous papers were not clear and were likely 
different to the 4 h preincubation used in our studies. As DMF can act as a covalent inhibitor it is able to display 
time dependent kinetics of inhibition (data not shown) and thus longer pre-incubation times might give a more 
pronounced inhibition of Iκ Bα degradation.
The effects we observed on NFκ B and MAPK activation could be explained by inhibition of TLR signaling 
at the level of K63/M1 polyubiquitin chain formation and thus blocking the activation of Tak1. If DMF did act 
at the level of Tak1 or ubiquitination, it would also be expected to inhibit p38 activation. This is complicated by 
the observation that p38 was activated by DMF alone (Fig. 6), which would obscure any effect of DMF on TLR 
induced p38 activation pathways. One potential mechanism would be the inhibition of tyrosine phosphatases, 
as this is known to activate MAPK signaling. This is however unlikely as DMF did not result in increased global 
levels of phosphotyrosine. Another explanation could be activation of a MAP3K for p38 and JNK. One possible 
candidate might be Ask1, which is also known to be expressed in macrophages and can contribute to p38 activa-
tion by LPS49. Ask1 is activated by oxidative stress via a complex mechanism involving Trx150. It is possible that 
DMF may activate Ask1 via modification of cysteine residues on Trx1 or via targeting proteins involved in the 
response to oxidative stress. Further work would be required to resolve this point.
Figure 9. Effect of DMF on LPS stimulated polyubiquitin chain formation in BMDMs. (A) BMDMs were 
incubated in the presence or absence of 50 μ M DMF for 4 h. Cells were then either left unstimulated or treated 
with 100 ng/ml LPS for a further 30 min. Halo-NEMO beads were used to pulldown M1 polyubiquitin chains. 
Pull downs were then immunoblotted with antibodies specific for M1 chains or IRAK2 (left hand panels). 
Alternatively the levels of IRAK1, phospho p105, phospho ERK1/2 and total ERK1/2 in the cell extracts were 
determined by immunoblotting (right hand panels). (B) As (A) but Halo-TUBE pull downs were used to isolate 
total ubiquitin chains and the pull downs blotted with antibodies against M1 and K48 chains.
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The effects of DMF on signaling have recently been suggested to have similarities to those produced by BAY 
11-708248. Interestingly while BAY 11-7082 was originally described as an IKK inhibitor a recent study has shown 
that BAY 11-7082 can act in cells via inhibiting E2 enzymes, including Ubc13 and UbcH745. As for DMF, the 
mechanism found for this involved the covalent modification of the active site cysteine in the E2.
Taken together our results, along with those of others, would indicate that DMF has complex effects in cells 
and is unlikely to act via a single target. Instead it is likely that the overall therapeutic effects of DMF in MS or 
psoriasis are due to the ability of DMF to directly modify the function of a number of cellular proteins via the 
modification of reactive cysteines in these targets. The finding that DMF - an approved drug in clinical use - and 
BAY 11-7082 can both target E2s involved in K63 and M1 polyubiquitin chain formation and have similar effects 
on cytokine production suggests that E2s may be useful drug targets for novel anti-inflammatory therapies.
Figure 10. Effect of DMF on IL-1 and TNF stimulated M1 chain formation. (A) IL-1R HEK293 cells were 
incubated with 50 μ M DMF for 4 h where indicated. Cells were stimulated with 5 ng/ml IL-1β for 30 min 
and the levels of phospho p105, phospho IKK, total Iκ Bα , phospho ERK1/2 and total ERK1/2 determined 
by immunoblotting. (B) As (A) but Halo-NEMO beads were used to pull down M1 polyubiquitin chains. 
Pulldowns were blotted for M1 and K63 linked polyubiquitin chains. (C) HeLa cells were incubated with 50 μ M 
DMF for 4 h where indicated. Cells were stimulated with 10 ng/ml TNF for 30 min and the levels of phospho 
p105, phospho IKK, total Iκ Bα , phospho ERK1/2 and total ERK1/2 determined by immunoblotting. (D) As  
(C) but Halo-NEMO beads were used to pull down M1 polyubiquitin chains. Pull downs were blotted for M1 
and K63 linked polyubiquitin chains.
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Methods
Chemicals. All chemicals, including DMF and MMF, were from Sigma unless otherwise stated.
Animals. C57Bl/6 mice were obtained from Charles River Laboratories. Nrf2 knockout mice have been 
described previously51 and backcrossed onto C57Bl/6 for 7 generations52. Knockouts of MSK1 and MSK2 have 
been described previously and mice used in these studies had been backcrossed onto C57Bl/6 for at least 20 
generations53. Animals were maintained in individually ventilated cages under specific pathogen free conditions. 
Mice were maintained in accordance with UK and EU regulations, and all protocols were covered by an appro-
priate Home Office license that was subject to approval by the University of Dundee Ethical Review Committee.
Cell culture. All cell culture reagents were from Gibco unless otherwise stated. RAW264.7 cells were main-
tained in DMEM supplemented with 10% heat-inactivated fetal bovine serum (FBS), 2 mM L-glutamine, 
100 units/ml penicillin G, 100 μ g/ml streptomycin. HEK293 cells stably overexpressing the IL-1 receptor54 and 
HeLa cells were maintained in DMEM supplemented with 10% FBS, 2 mM L-glutamine, 100 units/ml penicillin 
G, 100 μ g/ml streptomycin. Bone marrow derived macrophages (BMDMs) were isolated as described55. Briefly, 
freshly isolated bone marrow cells were differentiated in bacterial-grade plastic dishes in DMEM supplemented 
with 10% heat inactivated fetal bovine serum (Labtech), 4 mM L-glutamine, 100 units/ml penicillin G, 100 μ g/ml 
streptomycin, 0.25 μ g/ml amphotericin and 5 ng/ml M-CSF (PeproTech). After 7 days macrophages were pas-
saged onto tissue culture plastic and used the following day. Bone marrow derived dendritic cells (BMDCs) were 
prepared in a similar manner to BMDMs but 5 ng/ml GM-CSF (Peprotech) was used in place of M-CSF.
Analysis of cytokine induction. Following stimulation, the levels of TNF, IL-6, IL-10, IL-13 and GM-CSF 
present in the media was determined via a multiplex Luminex based method (Bioplex, BioRad) according to the 
manufacturer’s instructions. For measurement of mRNA induction, total RNA was isolated using the Omega 
MicroElute total RNA extraction kit (VWR). 0.5 to 1 μ g of total RNA was reversed transcribed (iScript, BioRad) 
and qPCR carried out using Sybrgreen based detection reagents (SYBR Premix ExTaqII #RR820L, Takara 
Biosciences). Fold induction was calculated from the unstimulated controls cells and GAPDH was used to correct 
for expression56. Primer sequences are shown in Table 1.
Flow cytometry. BMDMs were treated with 50 μ M DMF. To assess TNFα induction, cells were subsequently 
stimulated with 100 ng/ml LPS to induce cytokine, and cytokine secretion was blocked by treating cells with 3 μ g/ml 
Brefeldin-A and 2 μ M Monensin. Cells were detached by treatment with 1x trypsin for 5 min and gentle scrap-
ing. Cells were washed with PBS and the percentage of live cells was determined by staining with Zombie-Aqua 
(BioLegend) according to the manufacturer’s protocol. Briefly, cells were resuspended in 1:200 Zombie-Aqua in 
PBS and were incubated at room temperature in the dark for 10 minutes. Then, cells were washed with FACS buffer 
(1% BSA in PBS), fixed with Fixation buffer (eBiosciences) for 20 min at + 4 °C, washed with FACS buffer, perme-
abilised with 1x Permeabilisation buffer (eBiosciences) for 15 min at + 4 °C and washed with FACS buffer. Cells 
were incubated with 1:100 Fc block (BD Biosciences) in 1x permeabilisation buffer for 10 min at + 4 °C, and then 
stained for intracellular TNFα with TNFα -PE (eBiosciences) in 1x permeabilisation buffer for 20 min at + 4 °C. 
Stained cells were washed with FACS buffer, resuspended in FACS buffer and acquired in a BD FACSCanto™ II.
Immunoblotting. Cells were lysed in 50 mM Tris-HCl (pH 7.5), 1 mM EGTA, 1 mM EDTA, 1 mM sodium 
orthovanadate, 50 mM sodium fluoride, 1 mM sodium pyrophosphate, 0.27 M sucrose, 1% (vol/vol) Triton X-100, 
0.1% (vol/vol) 2-mercaptoethanol, 1 μ g/ml aprotinin, 1 μ g/ml leupeptin, 1 mM PMSF. Lysates were clarified by 
centrifugation (13,000 rpm for 10 min at 4 °C) and supernatants snap-frozen and stored at − 80 °C. Protein 
concentration was determined with Coomassie Protein Assay Reagent (Thermo Scientific). Proteins were sep-
arated on 10% polyacrylamide gels and immunoblotting carried out using standard techniques. Antibodies 
recognizing phospho-Thr202/Tyr204 ERK (#9101), total ERK (#9102), total JNK (#9258), phospho-Thr180/
Tyr182 p38 (#4511), total p38 (#9212), total IRAK1 (#4504), phospho-S133 P105 (#4806), total Iκ Bα (#4814), 
phospho-MKK3/MKK6 (#9321) and phospho-Ser177/Ser181 IKKβ (#2697) were from Cell Signaling 
Technology. A phospho-specific antibody that recognizes JNK phosphorylated at Thr183/Thr185 (#44682) was 
from Invitrogen. An antibody recognizing IRAK2 (#62419) was from Abcam. An antibody recognizing ubiquitin 
was from Dako (#Z0458), and antibodies recognizing Lys63-linked poly-ubiquitin (#HWA4C4), Lys-48-linked 
mRNA sense antisense
GAPDH ACAGTTCTTATGTGGTGACCC TGCACCACCAACTGCTTAG
TNF CAGACCCTCACACTCAGATCATC GGCTACAGGCTTGTCACTCG
IL-6 TTCCATCCAGTTGCCTTCTTG AGGTCTGTTGGGAGTGGTATC
IL-10 CCCTTTGCTATGGTGTCCTTTC GATCTCCCTGGTTTCTCTTCCC
GM-CSF CTCACCCATCACTGTCACCC TGAAATTGCCCCGTAGACCC
IL-12p40 TCATCAGGGACATCATCAAACC TGAGGGAGAAGTAGGAATGGG
IL-23p19 ATCCAGTGTGAAGATGGTTGTGAC TTCTAGTAGGGAGGTGTGAAGTTG
Iκ Bα ACACGTGTCTGCACCTAG TCAGACGCTGGCCTCCAAAC
IFNβ GGAAAAGCAAGAGGAAAGATTGAC CCACCATCCAGGCGTAGC
HO-1 CTAGCCTGGTGCAAGATA GAAGCTGAGAGTGAGGAC
Table 1. Primer sequences used for PCR.
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poly-ubiquitin (#05-1307/Apu2) and Lys-11-linked poly-ubiquitin (2A3/2E6) were from Merck-Millipore. The 
antibody recognizing linear M1-linked poly-ubiquitin has been described57. The antibody recognizing HOIP 
(S174D 4th bleed) was raised in sheep and purified by the Antibody Production Team of the DSTT, Medical 
Research Council Protein Phosphorylation and Ubiquitylation Unit, University of Dundee.
E1 and E2 ubiquitin loading assays. UbeE1 and E2s were expressed and purified as reported previously45. 
E1 and E2 ubiquitin loading assays were performed as described45. Briefly, UBE1 (0.17 μ M) was incubated with 
Ubc13 (2.4 μ M) or UbcH7 (2.9 μ M) and 10 μ M ubiquitin in 20 mM HEPES pH 7.5 with or without 1 μ l DMF for 
30 minutes at room temperature. A solution of 10 mM magnesium acetate and 0.2 mM ATP was added, reactions 
incubated at 30 °C for 10 minutes, and terminated by the addition of 5 μ l 4x NuPAGE LDS sample buffer. Samples 
were subjected to SDS-PAGE in the absence of thiol. Gels were stained for 1 h with Coomassie Instant Blue 
(Expedeon) and destained in water, before imaging and quantification using Licor Odyssey and ImageStudio 
software.
LUBAC E3 ligase activity assay. LUBAC E3 ligase activity assays were performed as described40. Briefly, 
1 μ g anti-HOIP was coupled to 10 μ l packed Protein-G sepharose beads in 50 mM Tris-HCl pH 7.5, 0.2% 
Triton X-100 for 2 h at 4 °C. The beads were washed 3x in lysis buffer and incubated with 1 mg cell extract for 
16 h at 4 °C. The beads were washed 3x in 50 mM Tris-HCl pH 7.5, 1% Triton X-100, 0.2 M NaCl, 0.05% (v/v) 
2-mercaptoethanol and once in 50 mM Tris-HCl pH 7.5, 5 mM MgCl2. The E3 ligase reaction was initiated by the 
addition of 20 μ l of 20 mM Tris-HCl pH 7.5, 2 mM DTT, 0.1 μ M UBE1, 0.4 μ M UbcH7, 10 μ M ubiquitin, 5 mM 
MgCl2, 2 mM ATP and incubated for 60 minutes at 30 °C. The reactions were terminated by the addition of 5 μ l 4x 
NuPAGE LDS sample buffer and samples were subjected to SDS-PAGE and immunoblotting with anti-ubiquitin 
antibody (DAKO #Z0458).
Generation of Halo-tagged proteins and pull-down assays. NEMO, TAB2-NFZ domain or 
tandem-repeated ubiquitin binding entities (TUBEs) were expressed as Halo-tagged proteins in E. coli and puri-
fied as described40. To capture M1-pUb and/or K63-pUb chains from cell extracts, 2–3 mg of cell extract was 
incubated with 20–30 μ l (packed beads) Halo-linked proteins for 16 h at 4 °C. The beads were washed 3x with 
50 mM Tris-HCl pH 7.5, 500 mM NaCl, 1% Triton X-100, transferred to Spin-X columns in 600 μ l Tris-HCl 
pH 7.5 and centrifuged twice to remove any supernatant. Proteins were denatured in NuPAGE LDS containing 
reducing agent, centrifuged to separate them from the beads and subjected to SDS-PAGE and immunoblotting.
Measurement of the molecular mass of Ubc13 and UbcH7 by MALDI-TOF-MS. Ubc13 (2.4 μ M) 
or UbcH7 (2.9 μ M) was incubated with 50 μ M DMF in 25 mM HEPES pH 7.5 for 4 h at room temperature, before 
buffer exchange into 5 mM Tris-HCl pH 7.5. An aliquot of the reaction (2 μ l, ~6 pmols) was added to 2 μ l of the 
matrix (2,5-dihydroxyacetophenone, 15 mg/ml in 80% EtOH, 20% 12 mg/ml ammonium citrate bibasic) and 2 μ l 
of 2%(v/v) trifluoroacetic acid was added before spotting 0.5 μ l of the sample on to an AnchorChip target (Bruker 
Daltonics). The analysis was performed manually in reflectron positive mode using a MALDI–TOF mass spec-
trometer (UltrafleXtreme, Bruker Daltonics). For external calibration, six average masses were used: insulin [M+ 
H]+avg (m/z 5734.520), cytochrome c [M+ 2H]2+avg (m/z 6181.050), myoglobin [M+ 2H]2+avg (m/z 8476.660), 
ubiquitin I [M+ H]+avg (m/z 8565.760) and cytochrome C [M+ H]+avg (m/z 12360.970).
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